Rimini Margherita Ricercatore tempo determinato tipo aMedicineMED/06 - Oncologia medica

From November 2016 to November 2021 medical oncology resident at University of Modena and Reggio Emilia.

From April 2021 to November 2021 clinical fellowship at Vall d’Hebron Institute of Oncology, Barcelona (Spain).

Active attendance at Multidisciplinary Disease Unit of Cholangiocarcinoma and Hepatocellular Carcinoma at IRCCS San Raffaele Hospital.

From January 2022, currently ongoing: Tutor for Residents in Medical oncology in the Vita-Salute San Raffaele University and for fellows from other institutions.

From January 2022, currently ongoing: Tutor for medicine students of traditional program and MD program in the Vita-Salute San Raffaele University.

From 2009 to 2015: Medical Degree at University of Modena and Reggio Emilia.

Grade: 110/110 cum Laude.

From 2016 to 2021: Residency in Medical Oncology at University of Modena and Reggio Emilia.

Grade: 110/110 cum Laude.

From May to November 2021: Clinical Fellowship at Vall d’Hebron Institute of Oncology (VHIO), Barcelona (Spain). Mentory: Dott.Teresa Macarulla Mercade.

Translational researches on biomolecular and genomic profile of cholangiocarcinoma, with a special focus on the clinical and therapeutic impact.

Real word investigations on the use of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients and investigations on the prognostic and predictive factors.

(Update january 2023)

Casadei-Gardini A*, Rimassa L*, Rimini M*, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol. 2021 Mar 20. doi: 10.1007/s00432-021-03602-w. Epub ahead of print. PMID: 33745079. 

Rimini M, Yoo C, Lonardi S, Masi G, Granito A, Bang Y, Rizzato MD, Vivaldi C, Ielasi L, Kim HD, Bergamo F, Salani F, Leoni S, Ryoo BY, Ryoo MH, Burgio V, Cascinu S, Casadei-Gardini A. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Target Oncol. 2021 Sep;16(5):653-661. doi: 10.1007/s11523-021-00834-1. Epub 2021 Sep 7. PMID: 34491510.

Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021 Nov 9:1-17. doi: 10.1080/17474124.2021.1991313. Epub ahead of print. PMID: 34669536.

Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res. 2021 Dec;51(12):1229-1241. doi: 10.1111/hepr.13718. Epub 2021 Oct 21. PMID: 34591334.

Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021 Dec;6(6):100330.

Casadei-Gardin A*, Rimini M*, Kudo M, Shimose S, Tada T, Suda G, Ji Goh M, Jefremow A, Scartozzi M, Cabibbo G, Campani G, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S (IN PRESS). REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study. Liver Cancer. Accepted on May 11th, 2022.

Della Corte A, Rimini M, Steidler S, Palumbo D, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A, De Cobelli F. Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments. Cardiovasc Intervent Radiol. 2022 Dec 7. doi: 10.1007/s00270- 022-03327-4. Epub ahead of print. PMID: 36478027. 

Rimini M, Loi E, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Raposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Zavattari P, CasadeiGardini A. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1- mutated clusters. Eur J Cancer. 2022 Nov;175:299-310. doi: 10.1016/j.ejca.2022.08.026. Epub 2022 Sep 28. PMID: 36182816.

Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S. Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer. 2022 Jul 11;11(6):527-539. doi: 10.1159/000525145. PMID: 36589723; PMCID: PMC9801178.

Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2022 Nov 25;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub ahead of print. PMID: 36527976.

Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. Sci Rep. 2022 Nov 5;12(1):18775. doi: 10.1038/s41598-022-22543-z. PMID: 36335135; PMCID: PMC9637171.

Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Lavacchi D, Personeni N, Ratti F, Pedica F, Della Corte A, Persano M, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis. Target Oncol. 2022 Sep;17(5):591- 596. doi: 10.1007/s11523-022-00917-7. Epub 2022 Sep 17. PMID: 36114954.

Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzoni M, Frassineti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Eur J Cancer. 2022 Aug;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21. PMID: 35749808